language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
ABTABT

$116.35

+0.09
arrow_drop_up0.08%
Market closed·update27 Feb 2026 21:02

$116.679

+0.33
arrow_drop_up0.28%
Post-market·update28 Feb 2026 00:55
Day's Range
115.58-116.815
52-week Range
105.27-141.23

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2026-01-22
Next Earnings TimeBefore Market Open
Volume7.91M
Average Volume 30d9.17M

AI ABT Summary

Powered by LiveAI
💰
17.9
Valuation (P/E Ratio)
Reasonable based on TTM data
📈
0.956
EPS Growth (YoY)
Significant earnings growth from 2023 to 2024
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Buy
75

Abbott Laboratories presents a balanced investment profile with strong fundamentals in the healthcare sector. While its valuation is moderate and technical indicators show mixed signals, its consistent dividend and diversified product portfolio offer stability. The company is well-positioned within established healthcare trends.

Neutral to Positive

Thematic

65

Abbott operates in stable, long-term growth sectors of healthcare. Its diverse product segments (diagnostics, medical devices, nutrition, established pharmaceuticals) provide resilience against specific market shifts. Emerging trends in personalized medicine and remote diagnostics are areas of opportunity.

Strong

Fundamental

82

Abbott Laboratories exhibits robust financial health with strong profitability, consistent revenue growth, and a healthy balance sheet. Its earnings have generally met or exceeded expectations, and it maintains a solid dividend payout.

Neutral to Bullish

Technical

70

The stock is trading below its 52-week high and shows mixed signals across different timeframes. While longer-term trends suggest underlying strength, short-term indicators point to a consolidating or slightly bearish sentiment.

FactorScore
Healthcare Demand85
Medical Device Innovation70
Diagnostic Capabilities80
Nutritional Products75
Pharmaceutical Pipeline50
FactorScore
Valuation70
Profitability95
Growth60
Balance Sheet Health75
Cash Flow85
Dividend70
Earnings Performance80
FactorScore
Trend Analysis60
Momentum50
Moving Averages (1D)40
Short-term Oscillators (15m)70
Volume Analysis (1D)50
Support & Resistance70

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (7)

Earnings Performance chevron_right

Consistent EPS Beat

The company has exceeded EPS estimates in the last 4 quarters, with positive surprises ranging from 0.1% to 26.85%, indicating robust earnings generation.

Valuation chevron_right

Attractive P/E Ratio

The trailing P/E ratio of 15.76 is lower than the industry average, suggesting the stock may be undervalued relative to its earnings.

Show More 🔒
thumb_down

Bearish Points (7)

Valuation Risk chevron_right

Elevated Quarterly P/E Ratio

The first quarter 2025 P/E ratio of 172.6 is exceptionally high, potentially indicating overvaluation or significant investor expectations for future growth.

Growth Deceleration chevron_right

Slowing Revenue Growth

While annual revenue in 2024 was strong, the trend in quarterly revenue shows a decrease from Q4 2024 ($10.97B) to Q1 2025 ($10.36B), potentially signaling a slowdown.

Show More 🔒

Calendar

July 2025

15

Ex-Dividend Date

August 2025

15

Next Dividend Date

October 2025

15

Next Earnings Date

EPS Est.
Revenue Est.

H: $1.32

A: $1.30

L: $1.28

H: 11.50B

A: 11.40B

L: 11.22B

Profile

Websiteabbott.com
Employees (FY)114K
ISINUS0028241000
FIGI-

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Seasonals

2025
2024
2023
2022
2021

Price Target

141.62 USD

The 39 analysts offering 1 year price forecasts for ABT have a max estimate of 159.00 and a min estimate of 120.12.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
1.73B (99.42%)
Closely held shares
10.1M (0.58%)
1.74B
Free Float shares
1.73B (99.42%)
Closely held shares
10.1M (0.58%)

Capital Structure

Market cap
218.59B
Debt
15.02B
Minority interest
0.00
Cash & equivalents
7.62B
Enterprise value
226B

Valuation - Summary

Market Cap
219B
Net income
12.2B(5.58%)
Revenue
32B(14.62%)
219B
Market Cap
219B
Net income
12.2B(5.58%)
Revenue
32B(14.62%)
Price to earning ratio (P/E)17.90x
Price to sales ratio (P/S)6.80x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
41.95B
COGS
18.71B
Gross Profit
23.24B
OpEx
16.42B
Operating Income
6.83B
Other & Taxes
-6.58B
Net Income
13.4B

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒